An analysis of health plans offered through Covered California found some consumers with chronic diseases or those who rely on specialty drugs may have faced access and affordability challenges in 2014.
An analysis of health plans offered through Covered California found some consumers with chronic diseases or those who rely on specialty drugs may have faced access and affordability challenges in 2014.
The report, written by Avalere Health and supported by the California HealthCare Foundation, analyzed drug coverage for the 100 most commonly prescribed drugs in the US commercial market and focused on 11 drug classes used to treat 5 common chronic conditions: HIV/AIDS, mental health, diabetes, autoimmune disorders, and asthma/chronic obstructive pulmonary disease.
The researchers discovered that while consumers with limited drug needs had comprehensive, affordable access to the most commonly used medications there was wide variation in the breadth of formularies among the different plans on Covered California. They found that the number of atypical antipsychotics available on formularies ranged from a low of just 5 listed drugs to a high of 11 products. For antidiabetics the range spanned from a low of 9 products to 44.
Analyzing plan tiers, the report found that products used to treat complex chronic conditions were disproportionately placed on the specialty tier in Covered California plans, which discourages consumers from using these drugs because of the high out-of-pocket costs.
“Since specialty drugs can cost several hundred to several thousand dollars per month, consumers who take these medications may experience high out-of-pocket costs until they reach the annual out-of-pocket cap, which was $6350 in 2014,” the authors wrote.
However, the report revealed that one plan had listed all of its HIV/AIDS drugs on the specialty tier, including generics and brands. This practice is not limited to Covered California as a paper in the New England Journal of Medicine found.
Another point of concern was the lack of comprehensive information on drug coverage and out-of-pocket costs. Even the researchers had difficulty finding comprehensive, easily understood information on drug cost and coverage information by health plan.
“This lack of access could be a barrier to consumers who wish to make informed purchase decisions,” the authors wrote.
With some chronically ill patients continuing to face access and affordability challenges in the individual market, Avalere presented policy changes to improve transparency:
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More